NEW YORK, April 2, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced the completion of enrollment in its latest phase II proof of concept trial (REP 301 protocol). This trial will examine the safety and efficacy of combined REP 2139-Ca and Pegasys® (peginteferon alfa-2a) treatment in patients with chronic hepatitis B / hepatitis D co-infection.
The REP 301 protocol (NCT02233075) is examining the safety and efficacy of REP 2139-Ca monotherapy followed by combination therapy with REP 2139-Ca and Pegasys® in patients with chronic hepatitis B / hepatitis D co-infection. This proof of concept trial is designed to achieve the following milestones:
1. Demonstrate the safety of REP 2139-Ca in monotherapy and when combined with Pegasys® in Caucasian patients.
2. Confirm the pharmacological effect of REP 2139-Ca (HBsAg release inhibition) observed in previous Asian trials (REP 102 and 201 protocols) in Caucasian patients.
3. Demonstrate combined antiviral efficacy against both hepatitis B and hepatitis D infections.
4. Assess SVR rates achievable with REP 2139-Ca / Pegasys® combination therapy.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com.